Ascendis Pharma A/S Sponsored ADR Aktie News

Ascendis Pharma is expected to achieve cash flow break even by the end of 2024, driven by its core franchise of medicines for rare endocrinology conditions. The company's approved drug, Skytrofa, has shown strong sales and has the potential to be a blockbuster. Ascendis Pharma's TransCon PTH, a parathyroid hormone replacement therapy, is awaiting FDA approval and has the potential to capture a ...

Ascendis Pharma A/S (ASND) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President & Chief Executive Officer Scott Smith - Executive Vice President & Chief Financial Officer Stina Singel - Executive Vice President, Clinical Development, Oncology Joe Kelly - US General Manager Conference Call Participant...

— Rollout of YORVIPATH ® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31

COPENHAGEN, Denmark, April 25, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2024 financial results and provide a business update on Thursday, May 2, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on May 2, 2024, at 4:30 p.m. Eastern Time (ET) to discuss its first q...

COPENHAGEN, Denmark, April 24, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom's Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for YORVIPATH® (palopegteriparatide; developed as TransCon™ PTH) in Great Britain as a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults ...

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

This biotech growth stock is climbing its way up a base on its way to a buy point. The company's sales are expected to continue to soar.

Procept BioRobotics and Ascendis Pharma may not show profits but the stocks have outperformed the S&P 500 in 2024. Shares are near buy points.